CLAIM #50443 · PM (PM) · 2026Q2 earnings call · Jul 22, 2026 · due Dec 31, 2026
“Supported by a rich product pipeline and improving regulatory clarity, we believe it is the right moment to accelerate U.S. investment in the second half of the year to support ZYN's brand equity and portfolio expansion and to prepare for the future launch of IQOS ILUMA.”
Emmanuel Babeau · CFO
How to check this claim
Look at: U.S. commercial/marketing investment spend behind ZYN and IQOS in H2 2026, as disclosed in management commentary (qualitative confirmation of increased spend, or SG&A/commercial investment trend for PM's U.S. smoke-free segment)
It came true if: Company reports or confirms increased U.S. investment behind ZYN and IQOS ILUMA preparation in H2 2026 versus H1 2026 or versus prior-year H2
Where: PMI Q3 2026 and Q4/FY2026 earnings releases and call commentary (management discussion of U.S. commercial investment)
In context
“Emmanuel Babeau: ZYN shipments increased by +2% to 2.9 billion pouches, despite an inventory tailwind in the prior year, broadly reflecting offtake trends and the initial shipments of new variants, including ZYN Ultra. We are excited about this first phase of portfolio expansion with additional initiatives planned in the coming months to enhance and enrich our offering to legal-age American nicotine consumers. Supported by a rich product pipeline and improving regulatory clarity, we believe it is the right moment to accelerate U.S. investment in the second half of the year to support ZYN's brand equity and portfolio expansion and to prepare for the future launch of IQOS ILUMA. Overall, our strong first half performance reinforces our confidence in our ability to consistently invest behind smoke-free growth opportunities while delivering another year of best-in-class top and bottom-line growth.”
Verify independently
SEC filings for PM ↗ · Claim quote is verbatim from the 2026Q2 earnings call.